Epidemiology, clinical characteristics, and outcome in candidemia: a retrospective five-year analysis from two tertiary general hospitals
- PMID: 40217142
- PMCID: PMC11992820
- DOI: 10.1186/s12879-025-10908-4
Epidemiology, clinical characteristics, and outcome in candidemia: a retrospective five-year analysis from two tertiary general hospitals
Abstract
Background: Candidemia is linked with high mortality, highlighting the critical importance of timely empirical antimicrobial therapy and precise medical intervention before a definite etiologic diagnosis. The current study aimed to investigate the prevalence of pathogens in patients with candidemia and evaluate the potential independent risk factors for Candida albicans bloodstream infections (BSI), as well as the prognosis of candidemia.
Methods: A retrospective bicentric observational study was performed, incorporating 132 candidemia episodes from two tertiary general hospitals in the Linyi area between January 2019 and December 2023. Data on demographic characteristics, underlying diseases, medical intervention, and antimicrobial sensitivity were collected and analyzed using SPSS version 27.0. Univariate analysis and binary logistic regression analyses were performed to identify risk factors for non-albicans Candida infections and candidemia-related mortality.
Results: A total of 132 strains of Candida species were isolated from 132 patients with candidemia, with non-albicans Candida accounting for 71.97% (95/132) and Candida albicans for 28.03%. Although Candida albicans remains the predominant species, the proportion of Candida tropicalis, mainly from the Hematology Ward, is approaching that of Candida albicans, which was mainly found in the intensive care unit (ICU) (27.27% versus 28.03%). Moreover, Candida tropicalis, the most frequently isolated non-albicans Candida species, exhibited poorer sensitivity to triazole drugs than other Candida species. Multivariate analysis identified gastrointestinal surgery (non-tumor) as an independent risk factor for Candida albicans BSI (odds ratio [OR] = 6.683, 95% confidence interval [CI]: 1.253-35.632, P = 0.026). The 30-day mortality rate of candidemia in the current study was 30.3%. Binary logistic regression analysis identified several factors significantly associated with mortality, including age (OR = 1.038, 95% CI: 1.007-1.071, P = 0.018) and septic shock (OR = 3.307, 95% CI: 1.205-9.071, P = 0.020).
Conclusion: The mortality rate of candidemia in the current study reached 30.3%, indicating a high disease burden. Recently, the proportion of non-albicans Candida, especially Candida tropicalis, has increased markedly. Therefore, increased attention should be given to patients with the identified risk factors to improve candidemia management and outcomes.
Clinical trial number: Not applicable.
Keywords: Candida species; Antifungal susceptibility; Candidemia; Mortality; Risk factors.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and approved by the Science and Technology Ethics Committee, Linyi People’s Hospital of Shandong Second Medical University (approval No.202408-H-013). Due to the retrospective and observational characteristics of the study, the Science and Technology Ethics Committee waived the requirement for informed consent. All patient data were anonymous prior to the analysis. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Epidemiological characteristics, antifungal susceptibility, and mortality factors of candidemia in adults at a tertiary teaching hospital in Zunyi, China (2016-2023).BMC Infect Dis. 2025 May 21;25(1):726. doi: 10.1186/s12879-025-11021-2. BMC Infect Dis. 2025. PMID: 40399823 Free PMC article.
-
Nineteen years retrospective analysis of epidemiology, antifungal resistance and a nomogram model for 30-day mortality in nosocomial candidemia patients.Front Cell Infect Microbiol. 2025 Feb 3;15:1504866. doi: 10.3389/fcimb.2025.1504866. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 39963405 Free PMC article.
-
Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.Mycopathologia. 2018 Aug;183(4):679-689. doi: 10.1007/s11046-018-0258-5. Epub 2018 Mar 23. Mycopathologia. 2018. PMID: 29572768
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Epidemiology of Candidemia, Candiduria and Emerging Candidozyma (Candida) auris Across Gulf Cooperative Council Countries and Yemen in the Arabian Peninsula.Mycoses. 2025 Jun;68(6):e70073. doi: 10.1111/myc.70073. Mycoses. 2025. PMID: 40491235 Free PMC article. Review.
Cited by
-
Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Pathogens. 2025 Aug 14;14(8):806. doi: 10.3390/pathogens14080806. Pathogens. 2025. PMID: 40872317 Free PMC article. Review.
-
Epidemiological characteristics, antifungal susceptibility, and mortality factors of candidemia in adults at a tertiary teaching hospital in Zunyi, China (2016-2023).BMC Infect Dis. 2025 May 21;25(1):726. doi: 10.1186/s12879-025-11021-2. BMC Infect Dis. 2025. PMID: 40399823 Free PMC article.
References
-
- Ferngren G, Yu D, Unalan-Altintop T, Dinnétz P, Özenci V. Epidemiological patterns of candidaemia: A comprehensive analysis over a decade. Mycoses. 2024;67(5):e13729. - PubMed
-
- Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJGT, Bohlius J, Wisplinghoff H, Vehreschild JJ. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 2021M020/the Traditional Chinese Medicine Science and Technology Development Program of Shandong Province
- 2021M020/the Traditional Chinese Medicine Science and Technology Development Program of Shandong Province
- 2021M020/the Traditional Chinese Medicine Science and Technology Development Program of Shandong Province
- 2024YX0024/the Key Research and Development Program of Linyi City
- 2024YX0024/the Key Research and Development Program of Linyi City
LinkOut - more resources
Full Text Sources